Concerns in the SESAMI Trial  by Pan, Xiaohong
Overall, regadenoson was well tolerated; side effects were generally
mild or moderate in severity and all self-limiting. Caffeine attenuated
the severity of side effects and improved tolerability of regadenoson.
The interaction of caffeine with adenosine-induced, dipyridamole-
induced, and even exercise-induced MBF changes (4,6) may limit the
correct detection of coronary artery disease and subsequently the proper
management of the patient, leading to the general recommendation to
withhold caffeine for 24 h before vasodilator stress testing (3). Because the
hyperemic MBF response to regadenoson after caffeine administration
lies well within the range of reported response to nonselective adenosine
receptor agonists and bicycle stress (6), the present study suggests that
regadenoson causes coronary hyperemia with and without prior caffeine
ingestion in healthy volunteers and moderate caffeine consumption may
not interfere with regadenoson stress MPI. Further study in patients with
coronary artery disease and possibly at higher caffeine doses would be
required before definitive conclusions could be drawn (8).
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Letters to the Editor
Concerns in the SESAMI Trial
In a clinical trial aiming to evaluate the safety and effectiveness
of drug-eluting stents in comparison with bare-metal stents
(BMS) in acute myocardial infarction (AMI), the description of
the end points should be clear and identical. As an important
composite clinical end point, major adverse cardiac events
(MACE) was given 3 possible full names without any definition
by Menichelli et al. (1) in the SESAMI (Sirolimus-Eluting
Stent Versus Bare-Metal Stent in Acute Myocardial Infarction)
trial, which could cause confusion. In the Methods section,
Figure 1 MBF Increased Significantly After Regadenoson
(A) Myocardial blood flow (MBF) at rest and after regadenoson; (B) regadenoson-induced coronary flow
reserve (CFR). Caffeine had no influence on resting or hyperemic MBF. Coronary flow reserve was not affected by caffeine.
329JACC Vol. 51, No. 3, 2008 Correspondence
January 22, 2008:328–32
MACE was the abbreviation of “major adverse cardiovascular
events.” In Table 4 and the related results part, MACE referred
to “major adverse coronary events.” Furthermore, “major ad-
verse cardiac events” appeared in the abstract and result part as
another full name of MACE. According to the recommenda-
tion of the Academic Research Consortium (2 ), the term
MACE can be device-oriented or patient-oriented. Without
any definition and identical full name of MACE in the
SESAMI trial, a formidable barrier was built to understanding
the results and to comparison with other clinical trials.
My other concern is the inclusion criteria of the patients. In the
Menichelli article (1), all the patients had AMI eligible for primary
angioplasty, which seemed to be confirmed later in the catheter-
ization and study procedure part. But in the slides presented by the
author in EuroPCR 2006 (3), the rate of rescue coronary angio-
plasty accounted for 17.5% in the sirolimus-eluting stent (SES)
group and 17.7% in the BMS group. The related information on
rescue percutaneous coronary intervention in the study design and
protocol should be described because it was a different treatment
strategy for AMI patients.
By the way, the value of standard deviation of stent diameter in
the SES group in Table 2 might be 0.34 instead of 0.034,
according to the context.
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Reply
We appreciate the effort made by Dr. Pan in emphasizing the need
for consistent end points in the medical literature. He refers to the
“formidable barrier” reported by Dr. Cutlip ( 1) in understanding
results across clinical trials. We agree that consistency across
well-considered end point definitions is critical.
In our trial (2), we used a device-oriented composite definition
of major adverse cardiac events (MACE). However, as Dr. Cutlip
reported, “composite acronyms such as MACE have been used so
frequently with so many variations in definition that the ARC
recommends that the term be avoided altogether.”
In designing the SESAMI (Sirolimus-Eluting Stent Versus
Bare-Metal Stent in Acute Myocardial Infarction) trial, we tried to
establish consistency among end point definitions. Indeed, this
trial was among the first to adopt and utilize the new Academic
Research Consortium definition of stent thrombosis—well before
Dr. Cutlip’s article was published.
As far as inclusion criteria are concerned, all of the patients
presented with ST-elevation myocardial infarction and were
eligible for primary angioplasty. We adopted the same strategy
for all the patients once they were in our catheterization
laboratory; however, a small portion of them had previously
received thrombolytic therapy, as reported in Table 1 of our
original study (2).
Dr. Pan surmises correctly that decimal point was mis-
placed in the standard deviation value for the sirolimus-eluting
stent diameter in Table 2 of our study (2). The correct value is
0.034.
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Resting Heart Rate and
Cardiovascular Disease: The
Beta-Blocker–Hypertension Paradox
The hypothesis of Fox et al. (1) of heart rate being an independent
predictor of cardiovascular and all-cause mortality in people with
and without diagnosed cardiovascular disease is convincing and
supported by a solid body of evidence. Considerably less well
documented is that pharmacologic heart rate slowing within the
physiologic range will reduce cardiovascular events or, indeed,
increase longevity. As Fox et al. (1) point out, it is likely that the
beneficial effect of beta-blockers after myocardial infarction and in
congestive heart failure is, at least to some extent, related to a
reduction in heart rate. However, the opposite seems to be true in
hypertension: we recently found a greater risk of cardiovascular
events (all-cause mortality, cardiovascular mortality, myocardial
infarction, stroke, and heart failure, all p  0.0001) with a lower
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